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Objectives: Due to its dramatically increasing prevalence, type 2 diabetes mel-
litus (T2DM) is a serious public health concern in Saudi Arabia. Few data have been 
published that describe how persons with T2DM are managed in clinical practice; 
we aimed to characterize recent treatment patterns among individuals treated 
for T2DM in Riyadh, Saudi Arabia. MethOds: Charts from 455 adults with T2DM 
who visited the King Fahad National Guard Hospital from October 2009 to March 
2010 (enrolment period) were systematically sampled until the target (n= 250) 
was reached. Treatment data from enrolment to September 2011 were abstracted 
from subject charts. Treatment regimens, their frequency of use, and the num-
ber of switches (drug replacement/removal/addition) over the study period were 
calculated. Analyses were stratified by T2DM duration; data for those recently-
diagnosed (< 5 years; n= 29) and with longstanding disease (≥ 20 years; n= 67) are 
presented. Results: Forty-four percent of subjects were male; at enrolment, mean 
(SD) age was 61 (13) years, and mean T2DM duration was 11 (8) years. At enrolment, 
42% of subjects had received prior insulin treatment (recently-diagnosed: 23%; long-
standing disease: 52%). During the study period, the most common regimens were 
oral combination therapy (41%) and insulin+oral combination therapy (32%). Overall, 
44% received any insulin therapy during the study period (recently-diagnosed: 25%; 
longstanding disease: 54%). By study end, 49% had received any prior insulin therapy 
(recently-diagnosed: 29%; longstanding disease: 58%). On average, T2DM subjects 
had 1.3 treatment switches over the period; little variation was seen by T2DM dura-
tion. cOnclusiOns: Although the frequency of insulin treatment was lower than 
reported in other studies from the region, treatment switches are indicative of 
attempts to improve T2DM control. Novel therapies may improve clinical outcomes 
among T2DM patients and this study provides valuable baseline data with which to 
compare the effectiveness of new T2DM treatments in Saudi Arabia.
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Objectives: SMBG is a core component of diabetes therapy, supporting a safe and 
effective drug therapy and providing feedback on the impact of diet and lifestyle. In 
2014 an Indian guideline on glycemic monitoring was published. This study aims 
to assess the level of SMBG usage in patients by diabetes therapies. MethOds: 
Source data for this explorative analysis is the CSD-PDS Diabetes survey covering 
drug treated patients with diabetes. All 2,250 cases were documented in the 2nd 
half of 2013. PDS Diabetes is a syndicated research with a fixed representative 
panel of doctors from larger Indian cities using a standardized documentation of 
cases. SMBG usage is analyzed by therapeutic subgroups: oral diabetes therapy 
(OAD 75%), basal supported oral therapy (BOT 9%), conventional insulin therapy 
(CT 8%), intensive insulin therapy (IIT 5%) and others (3%, excluded). Results: 
Diabetes type 2: 93%. 1,180 patients (52.4%) have a meter for home-testing. 
Shares of testers by therapies (OAD/ BOT/CT/IIT) are 50.7%, 63.4%, 53.1% and 
67.3%. An HbA1c-goal of 8% is achieved by 62/49/45/37%, an HbA1c-goal of 7% by 
29/20/19/18%. Average weekly test frequencies are 2.4, 2.8, 2.9 and 2.2 respectively. 
In the OAD/BOT/CT groups 13/14/16% test at least once daily (recommended), less 
than 2% in IIT test 3 times daily (recommended). HbA1c levels are by 0.3%, 0.2%, 
1.1% and 0.0% lower in SMBG users. cOnclusiOns: Many patients in this sample 
do not achieve HbA1c targets and many do not test their blood glucose. Below 1 
in 5 patients follows the recommended test frequency. In IIT SMBG is needed to 
support insulin dose adjustments: below 1 in 50 test enough. In CT patients the 
differences in HbA1c between testers and non-testers are largest. Lacking benefit 
in IIT treated patients might indicate the insufficiency of current testing. The new 
guideline might help to close these gaps.
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Objectives: To compare the efficacy and safety of Entecavir and Tenofovir in 
nucleos(t) ide-naïve CHB patients with HBV DNA in a medical center. MethOds: We 
included patients in WFH had used Entecavir or Tenofovir from 2011/07 to 2012/12, 
and excluded patients who had (1) co-infection with the HCV, HIV, TB, (2) the his-
tory of malignancy within 3 years before the first time use of ETV or TDF, (3) the 
history of alcohol abuse, and (4) used other anti-HBV drugs. In Statistics, we used 
Kaplan–Meier survival analysis to present the HBV DNA suppression and the nor-
malization of ALT. Results: We identified 124 consencutive patients treated with 
ETV and 24 patients treated with TDF. After 18 months, the probability of complete 
viral suppression was 67.7% in the ETV group and 45.8% in the TDF group (P= 0.49). 
The probability of complete ALT normalization was 87.1% in the ETV group and 
83.3% in the TDF group (P= 0.159). In the adverse side effects of neurologic, malaise 
was observed in the patients treated with ETV more than TDF (11.3% vs. 0%), but in 
gastrointestinal disorders, diarrhea was observed in the patients treated with TDF 
more than ETV (25.0% vs. 3.2%). cOnclusiOns: Entecavir and Tenofovir have no 
rithms compared to the conventinal glucose control using paper-based proto-
cols. MethOds: A systematic literature review and meta-analysis was used to 
evaluate the safety and effectiveness for the automated target glucose control. 
The 14 randomized control trials of 2537 articles were selected and two reviewers 
evaluated independently the quality of this selected articles using the Scottish 
Intercollegiate Guidelines Network (SIGN) tool. Results: The computer-based 
insulin protocols resulted in a shorter time to reach within target range (MD -1.03, 
95%CI -1.70~-0.35, p= .003, I2= 77%) and a higher percentage of glucose readings 
within target range (MD 11.98, 95%CI 8.83~15.14, p< .001, I2= 89%) than the paper-
based protocols. The incidence rates of above or below target range in computer-
based insulin protocols were acceptable levels and the incidence rates of severe 
hypoglycemia below 40mg/dL in computer-based insulin protocol was significantly 
lower than the paper-based insulin protocols (MD -23.41, 95%CI -32.35~-14.46, p< . 
001, I2= 0%). cOnclusiOns: The automated target glucose control using com-
puter-based algorithms resulted in tighter glycemic control without an increased 
risk of hypoglycemic events compared to the paper-based protocols. But taking 
into account the high heterogeneity between studies, these results must be inter-
preted with caution.
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Objectives: A comparisons of economic methods across all NICE submissions 
for SGLT-2is (dapagliflozin, canagliflozin and empagliflozin) and exploring poten-
tial opportunities for optimising the appraisals of treatment classes. MethOds: 
The NICE website was searched for: manufacturer submissions, clarification 
letters, evidence review group (ERG) reports and NICE guidance relating to the 
SGLT-2is. Data extracted included the sources of inputs and key assumptions to 
the economic analysis in particular the evidence synthesis, modelling approach 
and key cost-effectiveness results. Comparisons were then made across apprais-
als in reference to the ERG and NICE comments to identify any areas of uncer-
tainty. Results: The results of the review indicated the following similarities 
between submissions: The lines of therapies explored; the use of United Kingdom 
Prospective Diabetes Study equations to link surrogate to clinically relevant out-
comes; use of Bayesian network meta-analyses to derive clinical inputs which 
were all based on the same studies, outcomes and time period; the sources of 
cost and utility inputs were mainly derived from UKPDS studies; and the relative 
differences in costs and QALYS. The main differences identified included: the eco-
nomic models used (pre-existing versus de Novo); treatments included in decision 
space; the modelling of weight gain; definitions of adverse effects included; and 
the total costs and QALYs between appraisals. cOnclusiOns: The NICE apprais-
als for SGLT-2is were broadly similar in their overall design. This is apparent from 
the similar results of the appraisals in terms of relative outcomes. Given this, it is 
arguable whether the resources required to develop these separate submissions 
was essential. It would be of value for HTA organisations to develop reference 
cases including standard inputs for the modelling of significant conditions such 
as diabetes especially where there is such consistency. This would improve the 
comparability of analyses and reduce the costs to manufacturers and ERGs in 
developing and reviewing submissions respectively.
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Objectives: To assess adherence to UK NICE guidance/guidelines for initiating 
therapy with Glucagon-Like Peptide-1 [GLP-1] mimetics - exenatide, prolonged-
release exenatide [Exen-PR] and liraglutide – in patients with Type 2 diabetes 
(T2D). MethOds: A retrospective cohort study of T2D patients in primary care 
identified in the CPRD. Patients were ≥ 40 years at GLP-1 initiation, had ≥ 12 months 
of CPRD history, with first GLP-1 prescription recorded on/after publication of the 
respective NICE guidance/guideline. The primary outcome was the proportion of 
patients initiating/not initiating GLP-1 as part of a NICE-recommended regimen (rec-
ommended dual therapy: liraglutide or Exen-PR added to metformin or sulphonylu-
reas; recommended triple therapy: any GLP-1 added to metformin+sulphonylureas 
or metformin+thiazolidinedione). For patients initiating GLP-1 as triple therapy, 
the proportion meeting NICE initiation criteria (HbA1c ≥ 7.5% and body mass 
index [BMI] ≥ 35kg/m2) was assessed. Results: Mean age of the study cohort ini-
tiating GLP-1 (7,133 patients) was 58.2 years (SD 9.4), BMI 38.4 kg/m2 (SD 6.8) and 
HbA1c 9.2% (SD 3.2%). Overall, only 25% (1,772/7,133) of patients were initiated on 
GLP-1 as part of a NICE-recommended regimen. Approximately 13% of patients 
initiated liraglutide (443/3,438) and 13% initiated Exen-PR (45/346) as part of NICE-
recommended dual therapy regimen, with a higher proportion initiating a GLP-1 as 
part of NICE-recommended triple therapy (exenatide: 19% [637/3,349], liraglutide: 
17% [588/3,438], Exen-PR: 17% [59/346]). Of those patients initiated on a recom-
mended triple therapy regimen, 50% fulfilled both NICE HbA1c and BMI initiation 
criteria. The majority of the study cohort (75%) initiated GLP-1 in combination regi-
mens not recommended by NICE: 12% non-recommended dual therapy; 21% non-
recommended triple therapy; 16% monotherapy, and 25% quadruple therapy/add-on 
to insulin. cOnclusiOns: Many patients are initiated on GLP-1 in combination 
regimens which are not recommended by NICE. The rationale for these decisions 
may warrant further research to better understand the observed low adherence to 
NICE-recommended regimens.
